- ►hcvu.org [PDF] FJ Torriani, M Rodriguez-Torres, JK Rockstroh … - The New England journal of medicine, 2004 - nejm.highwire.org From the Department of Medicine, Division of Infectious Diseases, University of
Califor- nia, San Diego (FJT); the Fundacion de In- vestigacion de Diego,
Santurce, Puerto Rico (MR-T.); the University of Bonn, Bonn, Ger- many ... Cited by 729 - Related articles - BL Direct - All 16 versions
F Carrat, F Bani-Sadr, S Pol, E Rosenthal, F … - Jama, 2004 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Treatment of ... Cited by 405 - Related articles - BL Direct - All 10 versions
- ►tokb.ru [PDF] A Mangia, R Santoro, N Minerva, GL Ricci, V … - New England Journal of Medicine, 2005 - content.nejm.org From the Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza Hospital,
San Giovanni Rotondo (AM, RS, F. Spiri- to, AA); the Department of Internal Med-
icine, Hospital Canosa, Canosa (NM); the Department of Internal Medicine, ... Cited by 376 - Related articles - All 10 versions
M von Wagner, M Huber, T Berg, H Hinrichsen … - Gastroenterology, 2005 - Elsevier Background & Aims: Standard therapy of patients with chronic hepatitis C virus
(HCV) infected with HCV genotype-2 or -3 is the combination of pegylated
interferon-α and ribavirin for 24 weeks. Whether shorter treatment ... Cited by 256 - Related articles - All 14 versions
T Berg, M von Wagner, S Nasser, C Sarrazin, … - Gastroenterology, 2006 - Elsevier Background & Aims: The treatment of patients infected with hepatitis C virus
(HCV) type 1 remains a challenge necessitating innovative strategies to improve
treatment outcome. The extension of treatment duration beyond 48 weeks is ... Cited by 246 - Related articles - All 18 versions
S Zeuzem, M Buti, P Ferenci, J Sperl, Y … - Journal of hepatology, 2006 - Elsevier End-of-treatment and sustained virologic response rates were 80 and 50%,
respectively. The 48-week historical control (Manns et al., Lancet
2001;358:958–65) had similar end-of-treatment (74%) but higher sustained ... Cited by 244 - Related articles - All 11 versions
JJ Feld, JH Hoofnagle - Nature, 2005 - nature.com Since the identification of the hepatitis C virus, great strides have been made
in the development of an antiviral therapy. As a crucial mediator of the innate
antiviral immune response, interferon- (IFN- ) was a natural choice for ... Cited by 240 - Related articles - BL Direct - All 5 versions
O Dalgard, K Bjoro, KB Hellum, B Myrvang, S … - Hepatology, 2004 - interscience.wiley.com The aim of this study was to determine the efficacy of 14 weeks of treatment in
patients infected with hepatitis C virus (HCV) genotype 2 or 3 who achieve early
virological response (EVR). In a noncontrolled multicenter trial, 122 ... Cited by 224 - Related articles - All 5 versions
P Ferenci, MW Fried, ML Shiffman, CI Smith, … - Journal of hepatology, 2005 - Elsevier 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early
virological responses (HCV RNA negative or ≥2 log 10 decrease) at week 12 had
SVRs at week 72 (HCV RNA <50 IU/mL). The negative predictive value (NPV) ... Cited by 216 - Related articles - All 9 versions
DM Jensen, TR Morgan, P Marcellin, PJ … - HEPATOLOGY-BALTIMORE THEN ORLANDO-, 2006 - illinois-liver.org Approximately one third of hepatitis C virus (HCV) genotype 1 patients achieved
a sustained virological response (SVR) after 24 weeks of treatment with
peginterferon -2a (40 kd) plus ribavirin in a randomized, multinational ... Cited by 198 - Related articles - View as HTML - BL Direct - All 5 versions
